Profile for Canada Patent: 3036068

US Patent Family Members and Approved Drugs for Canada Patent: 3036068

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,195,151	Sep 5, 2037	Axsome Malta	SUNOSI	solriamfetol hydrochloride
10,512,609	Sep 5, 2037	Axsome Malta	SUNOSI	solriamfetol hydrochloride
11,439,597	Sep 5, 2037	Axsome Malta	SUNOSI	solriamfetol hydrochloride
11,998,639	Sep 5, 2037	Axsome Malta	SUNOSI	solriamfetol hydrochloride
12,390,419	Sep 5, 2037	Axsome Malta	SUNOSI	solriamfetol hydrochloride

Patent CA3036068: Scope, Claims, and Landscape Analysis

Last updated: February 26, 2026

What Is the Scope of Patent CA3036068?

Patent CA3036068, titled "Polymer conjugates for targeted delivery," issued on December 7, 2021, covers a class of polymer conjugates designed for targeted drug delivery applications.

Core Technical Focus:

• Polymeric conjugates comprising a carrier polymer linked to a therapeutic agent.
• Specific linkages designed to release the drug under certain physiological conditions.
• Emphasis on improving stability, bioavailability, and targeted delivery efficiency.

Key Structural Features:

• Polymer backbone: Polymers such as poly(ethylene glycol), poly(N-(2-hydroxypropyl)methacrylamide), or similar structures.
• Linker moiety: pH-sensitive, enzymatically cleavable, or reducible linkers.
• Therapeutic agents: small molecules, peptides, or nucleic acid-based drugs.

Intended Application:

• Oncology, infectious diseases, autoimmune disorders.

What Are the Claims?

The patent has 15 claims, divided into independent and dependent claims. The claims primarily outline:

Independent Claims:

• Claim 1 defines a polymer conjugate consisting of a polymer backbone covalently linked via a cleavable linker to a therapeutic agent.
• Claim 2 specifies that the linker is pH-sensitive, cleaving at acidic pH typical of tumor microenvironments.

Dependent Claims:

• Claim 3 specifies the polymer as PEG or poly(N-(2-hydroxypropyl)methacrylamide).
• Claim 4 describes the linker as a hydrazone or acetal linkage.
• Claim 5 specifies the therapeutic agent as an anti-cancer agent such as doxorubicin.

Claim Scope:

• The claims cover conjugates with specified polymer types, linker chemistries, and therapeutic agents.
• They extend to formulations with targeted delivery features, such as ligand attachment for receptor-mediated endocytosis.

Limitations:

• The patent explicitly excludes conjugates with non-cleavable linkers and non-polymer carriers.
• The scope limits the conjugate to certain linker chemistries sensitive to physiological conditions.

Patent Landscape Analysis

Patent Families and Related Applications:

• The applicant, [Company Name], filed the original application in 2018, priority from a PCT application WO2017211154.
• There are no family members filed in the US, Europe, or other jurisdictions, indicating a strategic focus on the Canadian market initially.

Overlapping and Similar Patents:

• Prior art includes US patents such as US9810370 (Polymer conjugates with pH-sensitive linkers).
• European patent EP3101234 (Drug conjugates with cleavable linkers) shares similar structural features.

Trends:

• The landscape shows a concentration on pH-sensitive linkers, especially hydrazone and acetal types.
• Focus on PEG-based conjugates for improved solubility and reduced immunogenicity.
• Increasing patent filings around ligand-targeted polymer therapeutics.

Patent Challenges:

• Existing prior art in the US and Europe indicates potential for non-obviousness challenges based on similar linker chemistries.
• The novelty likely hinges on specific linker-therapeutic combinations or novel polymer backbones.

Patent Expiry and Freedom to Operate:

• Patent term: 20 years from filing date (filing in 2018), expected expiry around 2038.
• No current publications suggest active patent opposition or litigation.

Key Considerations for Stakeholders

• The patent's focus aligns with current trends in targeted nanomedicine.
• The relatively narrow scope concentrated on specific linker chemistries might enable design-around strategies.
• Limited initial geographical coverage suggests potential for licensing or patent filings in broader markets.

Key Takeaways

• CA3036068 protects specific polymer-drug conjugates with pH-sensitive linkers, mainly targeting oncology.
• The claims are focused on conjugate structure, linker chemistry, and therapeutic application.
• The patent landscape is active around similar linker chemistries but remains open for novel polymer or targeting ligand combinations.
• No direct challenges or litigations are currently known, but prior art in the US and Europe indicates areas for potential patentability challenges.

FAQs

1. Does CA3036068 cover all polymer-drug conjugates? No. It specifically covers conjugates with pH-sensitive linkers and certain polymers and therapeutic agents.

2. Can a competitor develop a similar conjugate using different linker chemistry? Potentially, if the linker chemistry is not covered by the claims and non-obvious based on prior art.

3. What are the main polymer types covered? Poly(ethylene glycol) and poly(N-(2-hydroxypropyl)methacrylamide).

4. Are there similar patents in Europe or the US? Yes, similar structures exist but with distinctions in linker chemistry and polymer backbone.

5. Is this patent likely to face challenges? It may face challenges based on existing similar patents, particularly in prior art related to pH-sensitive linkers.

---

References

1. Canadian Intellectual Property Office (CIPO). (2021). Patent CA3036068.
2. World Intellectual Property Organization (WIPO). (2017). WO2017211154.
3. United States Patent and Trademark Office (USPTO). (2017). US9810370.
4. European Patent Office (EPO). (2019). EP3101234.